Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency

25 Feb 2022

Abstract excerpt

Triple-negative breast cancer (TNBC) is a highly aggressive disease with historically poor outcomes, primarily due to the lack of effective targeted therapies. Here, we established a drug sensitivity prediction model based on the homologous recombination deficiency (HRD) using 83 TNBC patients from TCGA. Through analyzing the effect of HRD status on response efficacy of anticancer drugs and elucidating its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35281113
DOI: 10.3389/fcell.2022.845950

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair DeficiencyPMID 35281113Read ↗

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read ↗

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Semantic proximity Read ↗

qRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancerSemantic proximity Read ↗

Identification of a novel gene signature with DDR and EMT difunctionalities for predicting prognosis, immune activity, and drug response in breast cancerSemantic proximity Read ↗

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerSemantic proximity Read ↗

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerSemantic proximity Read ↗

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.Semantic proximity Read ↗

A multiomics signature highlights alterations underlying homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Homologous repair deficiency score for identifying breast cancers with defective DNA damage responseSemantic proximity Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.